Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook

Simply Wall St.

Nov 30

Ultragenyx Pharmaceutical (RARE) captured attention after a recent analyst update on its setrusumab clinical program. This development coincided with reports of strong revenue growth and increasing ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2587798864"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2587798864\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2587798864?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-11-30 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2587798864","market":"sg","top_or_hot":-1,"title":"Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook","media":"Simply Wall St.","content":"<div>\n<p>Ultragenyx Pharmaceutical (RARE) captured attention after a recent analyst update on its setrusumab clinical program. This development coincided with reports of strong revenue growth and increasing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-pharmaceutical-rare-evaluating-valuation-after-an\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ultragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUltragenyx Pharmaceutical (RARE): Evaluating Valuation After Analyst Commentary on Setrusumab Progress and Growth Outlook\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-30 08:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-pharmaceutical-rare-evaluating-valuation-after-an><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Ultragenyx Pharmaceutical (RARE) captured attention after a recent analyst update on its setrusumab clinical program. This development coincided with reports of strong revenue growth and increasing ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-pharmaceutical-rare-evaluating-valuation-after-an\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065732104.USD","symbol_name":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-pharmaceutical-rare-evaluating-valuation-after-an","article_id":"2587798864","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-pharmaceutical-rare-evaluating-valuation-after-an","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2587798864","pubTimestamp":1764462149,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Ultragenyx Pharmaceutical (RARE) captured attention after a recent analyst update on its setrusumab clinical program. This development coincided with reports of strong revenue growth and increasing momentum behind several late-stage drug candidates.\nSee our latest analysis for Ultragenyx Pharmaceutical.\nUltragenyx’s recent surge in activity, including clinical milestones and upbeat revenue reports, appears to have lifted investor sentiment. A robust 16% 90-day share price return reflects...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","BK4097":"系统软件","RARE":"Ultragenyx Pharmaceutical Inc","BK4139":"生物科技","PRGS":"Progress Software Corporation"},"translate_title":"Ultragenyx Pharmaceutical（罕见）：在分析师对Setrusumab进展和增长前景发表评论后评估估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RARE":1.5,"PRGS":1.5},"content_text":"Ultragenyx Pharmaceutical (RARE) captured attention after a recent analyst update on its setrusumab clinical program. This development coincided with reports of strong revenue growth and increasing momentum behind several late-stage drug candidates. See our latest analysis for Ultragenyx Pharmaceutical. Ultragenyx’s recent surge in activity, including clinical milestones and upbeat revenue reports, appears to have lifted investor sentiment. A robust 16% 90-day share price return reflects renewed optimism. Still, with a 12-month total shareholder return of -27% and shares trading at $34.75, the long-term trend suggests the company is still working to rebuild momentum after a tougher stretch for biotech stocks. If recent clinical progress sparked your interest, it could be the right moment to explore other promising names. See the full list of healthcare standouts with our See the full list for free.. With Ultragenyx trading well below analyst targets and showing accelerating clinical and commercial progress, the real question is whether the market is overlooking its upside or if anticipated growth is already priced in. AdvertisementMost Popular Narrative: 58.3% Undervalued Ultragenyx finished last at $34.75, which is significantly below what the most widely followed narrative identifies as fair value. This substantial gap highlights the importance of new analyst projections and upcoming clinical milestones that could influence the stock if achieved.  Ultragenyx's clinical pipeline is advancing with five Phase III programs (including UX143 and GTX-102), multiple BLA submissions expected in the coming quarters, and near-term Phase III data readouts (notably for UX143 in OI by year-end and GTX-102 in Angelman syndrome in 2026) serving as upcoming value inflection points that can diversify and significantly accelerate the company's revenue base.  Read the complete narrative. Want to know what’s powering such a bold valuation target? The most crucial lever in this narrative is a growth surge, supported by optimistic forecasts for both revenues and margins. Elements within these projections could have a dramatic impact on the overall story. Find out which assumptions are driving the ambitious price target and why even small changes could significantly affect the outcome. Result: Fair Value of $83.40 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, persistent losses or unexpected regulatory setbacks could quickly undermine current optimism and limit any near-term upside for Ultragenyx shareholders. Find out about the key risks to this Ultragenyx Pharmaceutical narrative.  Build Your Own Ultragenyx Pharmaceutical Narrative If you see the story differently or want to dig deeper into the numbers, you can craft your own narrative in just a few minutes with Do it your way. A great starting point for your Ultragenyx Pharmaceutical research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision. Looking for more investment ideas? Don’t let your research end here. Take the next step toward your investing goals with tools designed to uncover standout opportunities you might be missing.  Boost your income potential with these 15 dividend stocks with yields > 3% that feature attractive yields above 3 percent and reliable payout histories. Catch the next tech transformation by screening these 25 AI penny stocks on the frontier of artificial intelligence innovation and high-growth potential. Seize value opportunities now by reviewing these 919 undervalued stocks based on cash flows, showcasing stocks that could be trading below their intrinsic worth.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}